Skip to main content
. 2016 Jan 21;59(3):1078–1101. doi: 10.1021/acs.jmedchem.5b01685

Figure 7.

Figure 7

Reduction of (A) tumor volume and (B) tumor weight versus vehicle-treated controls after chronic oral dosing (30 mg/kg q.d.) of 109 to an APC-mutant SW620 human colorectal carcinoma xenograft animal model. (C) Free plasma and free tumor exposure (nM) at 1, 2, 6, and 24 h after the last dose in the same experiment.